Activated protein C for H1N1 influenza? More work to do!

Critical Care

Volumn 14, Issue 3, 2010, Pages

  LaRosa, Steven P ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN C; PLASMINOGEN ACTIVATOR INHIBITOR 3; SERINE PROTEINASE INHIBITOR;

CELL SURVIVAL; FIBRINOLYSIS; INFLAMMATION; INFLUENZA A (H1N1); MORTALITY; NEUTROPHIL; NONHUMAN; NOTE; PRIORITY JOURNAL; ANIMAL; ANIMAL MODEL; DRUG EFFECT; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; MOUSE; ORTHOMYXOVIRUS INFECTION; PATHOPHYSIOLOGY; VIROLOGY;

ANIMALS; FIBRINOLYSIS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MICE; MODELS, ANIMAL; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN C INHIBITOR; SERINE PROTEINASE INHIBITORS;

EID: 79952113253     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc8994     Document Type: Note

References (15)

1. Schouten M, Sluijs KF, Gerlitz B, Grinnell BW, Roelofs JJTH, Levi MM, van't Veer C, Poll T. Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study. Crit Care 2010, 14:R65. 10.1186/cc8964, 20398279.
2. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SCB, Dhainaut JF. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005, 33:952-961. 10.1097/01.CCM.0000162381.24074.D7, 15891319.
3. To KKW, Hung IFN, Li IWS, Lee KL, Koo CK, Yan WW, Liu R, Ho KY, Chu KH, Watt CL, Luk WK, Lai KY, Chow FL, Mok T, Buckley T, Chan JFW, Wong SSY, Zheng B, Chen H, Lau CCY, Tse H, Cheng VCC, Chan KH, Yuen KY. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010, 50:850-859. 10.1086/650581, 20136415.
4. Liu KD, Levitt J, Zhuo H, Kallet R, Brady S, Steingrub J, Tidswell M, Siegel M, Soto G, Peterson MW, Chesnutt MS, Phillips C, Weinacker A, Thompson BT, Eisner MD, Matthay MA. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008, 178:618-623. 2542435, 18565951, 10.1164/rccm.200803-419OC.
5. Mosnier LO, Yang XV, Griffin JH. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem 2007, 282:33022-33033. 10.1074/jbc.M705824200, 17872949.
6. Choi G, Hoffstra JJ, Roelofs JJTH, Florquin S, Bresser P, Levi M, poll T, Schultz MJ. Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med 2007, 35:1362-1368. 10.1097/01.CCM.0000261888.32654.6D, 17414732.
7. Choi G, Vlaar APJ, Schouten M, van't Veer C, Poll T, Levi M, Schultz MJ. Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. Eur Respir J 2007, 30:423-428. 10.1183/09031936.00165606, 17537762.
8. White B, Schmidt M, Murphy C, Livingstone W, O'Toole D, Lawler M, O'Neill L, Kelleher D, Schwarz HP, Smith OP. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor κb (NF-κb) and tumour necrosis factor a production in the THP-1 monocytic cell line. Br J Hematol 2000, 110:130-134.
9. Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J, Gruber M, Zarini S, Murphy RC, Kuhn K, Richter D, Kast KR, Abraham E. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004, 104:3878-3885. 10.1182/blood-2004-06-2140, 15339848.
10. Waerhaug K, Kuklin VN, Kirov MY, Sovershaev MA, Langbakk B, Ingebresten OC, Ytrehus K, Bjertnaes LJ. Recombinant human activated protein C attenuates the endotoxin-induced lung injury in awake sheep. Crit Care 2008, 12:R104. 2575593, 18702832, 10.1186/cc6985.
11. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773.
12. Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP, Nelson DR, Lowry SF. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 2004, 21:222-229. 10.1097/01.shk.0000116778.27924.79, 14770034.
13. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, Stelfox T, Bagshaw S, Choong K, Lamontagne F, Tugeon AF, Lapinsky S, Ahern SP, Smith OR, Siddiqui F, Jouvet P, Khwaja K, McIntyre L, Menon K, Hutchison J, Hornstein D, Joffe A, Lauzier F, Singh J, Karachi T, Wiebe K, Olafson K, Ramsey C, Sharma S, Dodek P, et al. Critically Ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA 2009, 302:1872-1879. 10.1001/jama.2009.1496, 19822627.
14. Rello J, Rodriguez A, Ibanez P, Socias L, Cebrian J, Marques A, Guerrero J, Ruiz-Santana S, Marquez E, Del Nogal-Saez F, Alvaez-Lerma F, Martinez S, Ferrer M, Avellanas M, Granada R, Maravi-Poma E, Albert P, Sierra R, Vidaur L, Ortiz P, Prieto del Portillo I, Galvan B, Leon-Gil C. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care 2009, 13:R148. 2784367, 19747383, 10.1186/cc8044.
15. Gupta A, Gerlitz B, Richardson MA, Bull C, Berg DT, Syed S, Galbreath EJ, Swanson BA, Jones BE, Grinnell BW. Distinct functions of activated protein C differentially attenuate acute kidney injury. J Am Soc Nephrol 2009, 20:267-277. 2637057, 19092124, 10.1681/ASN.2008030294.